Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
/in Breast Cancer, Checkpoint-Inhibitors, Dendritic Cells, International PublicationsSafety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACtiVe-2 trial)
/in Dendritic Cells, International Publications, Pancreatic CancerCombination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsAutologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond
/in Dendritic Cells, Hypernephroma, International PublicationsEfficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsAutologous dendritic cells pulsed with allogeneic tumour cell lysate induce tumour-reactive T-cell responses in patients with pancreatic cancer: A phase I study
/in Dendritic Cells, International Publications, Pancreatic CancerWilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
/in Acute Leukemia, Dendritic Cells, International PublicationsA comprehensive update to Dendritic Cell therapy for glioma: a systematic review and meta-analysis
/in Dendritic Cells, Glioblastoma, International PublicationsSynergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer